Plant Science Review

PLANT SCIENCE REVIEW

Review Article

Journal homepage: https://psr.crcjournals.org/

ISSN No: 3041-7279

Traditional Knowledge Meets Modern Science in the Validation of Medicinal Plants for Neurological Disorders

Mihirkumar B. Suthar*[1], G. Ranganna[2], Sanjeev Kumar[3], Bhaskar Pathak[4] and Arijit Karmakar[5]

[1]*Department of Biology, K. K. Shah Jarodwala Maninagar Science College, BJLT Campus, Rambaug, Maninagar, ahmedabad-Gujarat 380008, India*

[2]*Dr. YSRHU-HRS, VR Gudem, West Godavari (District), 534101, Andhra Pradesh, India*

[3]*Krishi Vigyan Kendra, Shravasti, UP, 271831 (Acharya Narendra Deva University of Agriculture and Technology Kumarganj), Ayodhya, UP, 224229, India*

[4]*Department of Zoology, Gauhati University, Gopinath Bordoloi Nagar, Jalukbari, Guwahati, Assam 781014, India*

[5]*Department of Agronomy, Bidhan Chandra Krishi Vishwavidyalaya, Mohanpur, Nadia, West Bengal, India*

Received 15 June 2023 | Revised 21 July 2023 | Accepted 17 August 2023 | Available Online September 18 2023

*Corresponding Author: **Mihirkumar B. Suthar** | Email Address: **sutharmb@yahoo.co.in**

Citation: Mihirkumar B. Suthar, G. Ranganna, Sanjeev Kumar, Bhaskar Pathak and Arijit Karmakar (2023). Traditional Knowledge Meets Modern Science in the Validation of Medicinal Plants for Neurological Disorders. ***Plant Science Review***. **DOI: https://doi.org/10.51470/PSR.2023.04.02.19**

Abstract

Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and depression, remain a major global health challenge due to their complex pathophysiology and the limitations of current therapeutic options. Traditional medical systems such as Ayurveda, Traditional Chinese Medicine, and ethnomedicine have long employed medicinal plants for cognitive enhancement, seizure management, and mental health, yet these practices were historically underexplored by modern science. Advances in phytochemistry, pharmacology, molecular biology, and clinical research now enable systematic validation of these plant-based therapies. Bioactive phytoconstituents such as withanolides, bacosides, ginkgolides, curcumin, asiaticosides, and cannabinoids demonstrate neuroprotective properties through antioxidant, anti-inflammatory, cholinesterase-inhibitory, and neurotransmitter-modulating mechanisms. Increasing evidence from in vitro, in vivo, and clinical studies supports their therapeutic potential, while novel approaches including nanotechnology and advanced analytical tools enhance their efficacy and bioavailability. However, challenges persist regarding standardization, safety, dosage optimization, and regulatory approval. Bridging traditional knowledge with modern scientific validation not only strengthens the credibility of ethnopharmacology but also provides a promising pathway for the development of safe, effective, and multi-targeted therapies for neurological disorders.

Keywords: *Alzheimer's disease, epilepsy, and depression, molecular biology, therapies, and neurological disorders.*

Introduction

Neurological disorders are among the most pressing health challenges of the 21st century, affecting millions of individuals globally and placing a heavy socio-economic burden on families and healthcare systems. Conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), epilepsy, stroke, multiple sclerosis, and depression are increasing in prevalence due to rising life expectancy, urbanization, and lifestyle-related risk factors [1]. Current therapeutic approaches, though often effective in providing symptomatic relief, face limitations such as high costs, side effects, reduced efficacy over time, and inability to address the multifactorial causes underlying these disorders. These challenges underscore the urgent need for safe, affordable, and effective alternative or complementary treatment strategies.

Traditional medical systems—such as Ayurveda, Siddha, Unani, Traditional Chinese Medicine (TCM), Kampo medicine, and Indigenous ethnomedicine—have long relied on medicinal plants for managing neurological and mental health conditions. For centuries, communities have utilized herbs like *Bacopa monnieri* (Brahmi), *Withania somnifera* (Ashwagandha), *Centella asiatica* (Gotu kola), *Ginkgo biloba*, *Cannabis sativa*, and *Curcuma longa* (turmeric) to enhance cognition, reduce anxiety, improve sleep, or treat epilepsy [2]. These practices were developed through empirical knowledge, intergenerational transfer of wisdom, and careful observation of therapeutic effects [3].

Despite the lack of modern scientific validation in earlier eras, traditional knowledge has served as a foundation for identifying potential plant-based interventions for neurological health.

The integration of traditional knowledge with modern science is now gaining unprecedented attention. Advances in phytochemistry, pharmacology, molecular biology, and biotechnology have made it possible to identify, isolate, and characterize the active phytoconstituents responsible for neurological benefits. For instance, bacosides from *Bacopa monnieri* enhance memory and synaptic activity; withanolides from *Withania somnifera* reduce oxidative stress and promote neurogenesis; curcumin from turmeric exhibits strong anti-inflammatory and anti-amyloid properties; and ginkgolides from *Ginkgo biloba* improve cerebral blood flow and cognition [4]. These bioactive compounds often act through multiple pathways, including inhibition of acetylcholinesterase, modulation of neurotransmitters, enhancement of antioxidant defense systems, reduction of neuroinflammation, and regulation of neurotrophic factors such as BDNF (brain-derived neurotrophic factor).

Recent years have also witnessed the application of advanced analytical tools and molecular techniques in validating traditional plant-based therapies. Methods such as nuclear magnetic resonance (NMR), liquid chromatography-mass spectrometry (LC-MS), high-performance liquid chromatography (HPLC), and DNA barcoding enable accurate phytochemical profiling and quality control of herbal formulations. In parallel, *in vitro* studies using neuronal cell lines, in vivo animal models of neurodegenerative disease, and clinical trials in human populations provide evidence-based validation of safety and efficacy [5]. Moreover, nanotechnology-based delivery systems are being developed to enhance the bioavailability and stability of phytochemicals such as curcumin, resveratrol, and cannabinoids, which otherwise suffer from low solubility and poor pharmacokinetics.

The global interest in herbal medicine is also fueled by the rising demand for sustainable and eco-friendly healthcare solutions. Synthetic drugs, while indispensable, often generate adverse environmental and health impacts during production and use. In contrast, medicinal plants, when cultivated and harvested sustainably, offer renewable resources for drug discovery and development. Furthermore, plant-based therapies resonate well with patient preferences for natural, holistic, and culturally familiar treatment options [6]. Despite these advantages, significant challenges remain in the validation and mainstreaming of medicinal plants for neurological disorders. These include variability in plant composition due to environmental and genetic factors, lack of standardized extraction and formulation protocols, difficulty in determining safe and effective dosage levels, and limited large-scale clinical trials. Regulatory hurdles also exist, as herbal drugs must meet rigorous quality, safety, and efficacy standards before being accepted into modern healthcare systems. Additionally, the risk of overexploitation of medicinal plants and loss of biodiversity highlights the need for conservation strategies alongside scientific exploration.

Integrating traditional knowledge with modern science thus represents a two-way enrichment: traditional practices provide a vast repository of candidate plants and formulations, while modern research tools offer the means to validate, refine, and optimize their use in neurological health. This interdisciplinary approach not only honors the wisdom of ancient healing systems but also advances the discovery of novel therapeutic agents that are multi-targeted, cost-effective, and safe. The ultimate goal is to develop integrative healthcare solutions that bridge ethnomedicine and evidence-based medicine, thereby offering new hope for patients suffering from neurological disorders, explore the convergence of traditional knowledge and modern science in the validation of medicinal plants for neurological disorders. We highlight historical perspectives, key phytoconstituents, pharmacological mechanisms, advanced analytical techniques, clinical evidence, and future directions [7]. By doing so, we aim to emphasize the potential of medicinal plants as a complementary and integrative strategy in the prevention and management of neurological diseases, while addressing the challenges that must be overcome to realize their full therapeutic potential.

Table 1. Traditional Medicinal Plants Commonly Used for Neurological Disorders

Plant Name	Traditional System	Part Used	Neurological Indication	Example of Use
Bacopa monnieri (Brahmi)	Ayurveda	Leaves	Memory enhancer, anti-anxiety	Used in Ayurvedic formulations for cognitive support
Withania somnifera (Ashwagandha)	Ayurveda, Siddha	Roots	Stress, anxiety, neuroprotection	Rasayana tonic for nervous system
Ginkgo biloba	Traditional Chinese Medicine	Leaves	Dementia, Alzheimer's	Enhances cerebral blood flow
Centella asiatica (Gotu kola)	Ayurveda, TCM	Whole plant	Memory loss, epilepsy	Brain tonic
Valeriana officinalis (Valerian)	European herbal medicine	Roots	Insomnia, anxiety	Sedative effects

Table 2. Phytoconstituents and Their Neuroprotective Mechanisms

Plant	Major Bioactive Compound(s)	Mechanism of Action	Neurological Effect
Bacopa monnieri	Bacosides	Enhances synaptic activity, antioxidant	Improves memory, reduces anxiety
Withania somnifera	Withanolides	Reduces oxidative stress, modulates GABA receptors	Neuroprotection, anti-stress
Ginkgo biloba	Flavonoids, Terpenoids	Enhances cerebral blood flow, reduces ROS	Slows cognitive decline
Curcuma longa (Turmeric)	Curcumin	Anti-inflammatory, inhibits amyloid aggregation	Alzheimer's prevention
Valeriana officinalis	Valerenic acid	Modulates GABAergic transmission	Sedative, anxiolytic

Table 3. Modern Scientific Validation of Medicinal Plants

Plant	Model Used (In vitro/In vivo/Clinical)	Outcome	Reference/Study
Bacopa monnieri	Clinical trial in elderly	Improved memory and cognitive function	Randomized controlled trial
Withania somnifera	Animal models of stress	Reduced corticosterone, improved neuroprotection	Preclinical study
Ginkgo biloba	Clinical trial in Alzheimer's patients	Slowed cognitive decline	Double-blind trial
Centella asiatica	In vitro neuronal cell cultures	Enhanced neurite growth, antioxidant	Laboratory study
Curcuma longa	Animal model of Alzheimer's	Reduced amyloid plaques, improved cognition	Preclinical study

Table 4. Challenges in Herbal Neurological Drug Development

Challenge	Descriptio	Impact
Standardization	Variability in plant sources and extraction	Inconsistent efficacy
Safety and Toxicity	Dose optimization, long-term effects unknown	Limits clinical acceptance
Polypharmacology	Complex interactions of multiple compounds	Difficult to isolate mechanism
Regulatory Hurdles	Lack of harmonized global standards	Delays in commercialization
Bridging Knowledge Gaps	Traditional knowledge underutilized	Slows drug discovery

2. Traditional Knowledge and Medicinal Plants for Neurological Disorders

2.1 Historical and Cultural Perspectives

Traditional medicine has been central to healthcare for millennia, with plant-based remedies forming the foundation of most healing systems. Neurological disorders, though differently described in ancient texts, were managed with plants known to calm the mind, improve memory, and restore balance. For example, Ayurveda classifies certain herbs as *Medhya Rasayanas* (nootropic tonics) for enhancing intellect and memory. In Traditional Chinese Medicine (TCM), formulations containing *Ginkgo biloba*, *Panax ginseng*, and *Polygala tenuifolia* were prescribed for "Qi imbalance" and cognitive decline. Indigenous systems in Africa and the Americas similarly relied on plants such as *Cannabis sativa* and *Passiflora incarnata* to reduce seizures and anxiety [8].

These historical uses provided the first evidence that plants could exert beneficial effects on the brain and nervous system. Today, many of these ethnobotanical leads are being revisited through modern research to isolate active compounds and understand their mechanisms.

2.2 Commonly Used Medicinal Plants in Neurological Health

- **Bacopa monnieri (Brahmi):** Widely used in Ayurveda for memory enhancement and anxiety reduction. Contains bacosides that promote synaptic communication.
- **Withania somnifera (Ashwagandha):**
- A neuroprotective adaptogen that reduces stress-induced neuronal damage and improves neuroplasticity.
- **Centella asiatica (Gotu kola):** Traditionally used to enhance memory and treat mental fatigue. Rich in triterpenoids with neurotrophic properties.
- **Ginkgo biloba:** A TCM herb that improves cerebral circulation and has been investigated for dementia and cognitive decline.
- **Curcuma longa (Turmeric):** Curcumin reduces neuroinflammation, oxidative stress, and amyloid plaque formation in Alzheimer's disease models.
- **Cannabis sativa:** Traditionally used in pain management and epilepsy, now scientifically validated with cannabinoids like CBD and THC.

2.3 Traditional Formulations vs. Single Compounds

Unlike modern drug development which isolates single molecules, traditional medicine often relies on polyherbal formulations. These offer synergistic effects, reduce toxicity, and address the multifactorial nature of neurological disorders. For instance, Ayurvedic formulations such as *Brahmi Ghrita* and TCM formulas like *Kai Xin San* combine multiple herbs to achieve cognitive and emotional balance [9]. However, the variability of plant composition and lack of standardization present challenges in translating these formulations into evidence-based medicine.

3. Modern Scientific Validation of Medicinal Plants

3.1 Phytochemical and Pharmacological Insights

Modern phytochemistry has enabled the identification of bioactive constituents from traditionally used plants. These molecules exhibit diverse pharmacological actions relevant to neurological health:

- **Antioxidant activity** (curcumin, resveratrol, withanolides) – reducing oxidative stress in neuronal cells.
- **Anti-inflammatory effects** (ginkgolides, bacosides) – suppressing microglial activation and neuroinflammation.

- **Neurotransmitter modulation** (galantamine from *Galanthus nivalis*, cannabinoids) – regulating dopamine, serotonin, and acetylcholine.
- **Amyloid-beta inhibition** (curcumin, green tea catechins) – preventing protein aggregation in Alzheimer's disease.
- **Neurogenesis stimulation** (withanolides, asiaticoside) – enhancing neuronal repair and plasticity [10].

3.2 Advanced Analytical Techniques in Validation

Several modern tools are applied to ensure authenticity, purity, and mechanistic insights into medicinal plants:

- **Chromatography:** HPLC, GC-MS, LC-MS for phytochemical fingerprinting.
- **Spectroscopy:** NMR, FTIR for structural characterization of compounds.
- **DNA Barcoding:** To authenticate plant identity and avoid adulteration.
- **Omics Approaches:** Transcriptomics and metabolomics to explore molecular pathways influenced by phytoconstituents.

3.3 Experimental and Clinical Evidence

- **In vitro studies:** Neuronal cell cultures (e.g., SH-SY5Y cells) are used to evaluate antioxidant and anti-apoptotic effects of plant extracts.
- **In vivo animal models:** Rodent models of Alzheimer's, Parkinson's, and epilepsy demonstrate improved cognition and reduced neuronal damage after herbal treatment.
- **Clinical trials:** *Bacopa monnieri* has shown memory-enhancing effects in healthy adults, *Ginkgo biloba* has been studied for dementia, and cannabinoids are FDA-approved for certain forms of epilepsy [10].

3.4 Integration into Drug Discovery

Modern drug discovery often starts with traditional plant leads. For example, **galantamine**, now an FDA-approved Alzheimer's drug, was derived from *Galanthus nivalis* (snowdrop). Similarly, cannabinoid-based drugs for epilepsy highlight the transition from ethnomedicine to pharmaceutical application [11].

4. Mechanisms of Action of Medicinal Plants in Neurological Disorders

The therapeutic efficacy of medicinal plants in neurological disorders is primarily attributed to their rich repertoire of bioactive compounds that target multiple pathogenic mechanisms. One of the most studied pathways is the antioxidant defense system, as oxidative stress is a major contributor to neuronal degeneration. Phytochemicals such as curcumin, resveratrol, bacosides, and withanolides scavenge reactive oxygen species (ROS), upregulate endogenous antioxidants like superoxide dismutase (SOD) and catalase, and protect neurons from lipid peroxidation-induced damage. This antioxidant potential forms a fundamental basis for the neuroprotective activity of many herbal remedies [12].

Another important mechanism is the modulation of neurotransmitter systems. Certain phytoconstituents influence the synthesis, release, and breakdown of key neurotransmitters such as acetylcholine, serotonin, dopamine, and GABA. For instance, alkaloids from *Galanthus nivalis* inhibit acetylcholinesterase, thereby enhancing cholinergic transmission in Alzheimer's disease. Similarly, cannabinoids from *Cannabis sativa* interact with the endocannabinoid system to regulate excitatory and inhibitory neurotransmission, making them effective in conditions such as epilepsy and anxiety. Herbal adaptogens like *Withania somnifera* also modulate GABAergic and serotonergic signaling, contributing to anxiolytic and antidepressant effects [13]. Inflammation in the central nervous system, mediated by activated microglia and elevated pro-inflammatory cytokines, is another hallmark of neurodegenerative diseases. Medicinal plants exert anti-inflammatory actions by downregulating NF-κB signaling and suppressing the release of cytokines such as TNF-α, IL-1β, and IL-6. For example, ginkgolides from *Ginkgo biloba* and curcumin from *Curcuma longa* have demonstrated the ability to inhibit microglial activation, thereby reducing neuroinflammation and preserving neuronal integrity [14].

Medicinal plants also play a role in preventing protein misfolding and aggregation, a key pathological process in disorders like Alzheimer's and Parkinson's disease. Curcumin, green tea catechins, and asiaticoside from *Centella asiatica* have shown inhibitory effects on amyloid-beta aggregation and tau hyperphosphorylation, both of which are strongly implicated in Alzheimer's disease pathology. Similarly, natural polyphenols can prevent the aggregation of α-synuclein, a major culprit in Parkinson's disease.

Finally, some plant compounds stimulate neurogenesis and synaptic plasticity, critical processes for cognitive function and recovery after injury. Withanolides from *Withania somnifera* and bacosides from *Bacopa monnieri* enhance brain-derived neurotrophic factor (BDNF) expression and synaptic signaling pathways, promoting neuronal repair and strengthening memory circuits. These multifaceted mechanisms highlight the holistic potential of medicinal plants to address the complexity of neurological disorders, where single-target drugs often fail.

5. Challenges and Future Directions

Despite the compelling evidence supporting the neuroprotective effects of medicinal plants, several challenges hinder their widespread clinical application. One of the foremost issues is the variability in plant quality and phytochemical composition, which can be influenced by factors such as soil conditions, climate, harvesting time, and processing methods. This lack of consistency often leads to variation in therapeutic outcomes and complicates standardization for clinical use.

Moreover, many traditional formulations consist of multiple plant components, making it difficult to identify the precise active ingredients and their synergistic interactions. Another challenge lies in the bioavailability and pharmacokinetics of herbal compounds. Many phytoconstituents, such as curcumin and resveratrol, have poor solubility and rapid metabolism, resulting in low systemic availability. Innovative drug delivery strategies, including nanoformulations, liposomes, and phytosomes, are being explored to enhance their absorption and targeted delivery to the brain [15-16]. Without such technological interventions, the clinical efficacy of promising herbal compounds remains limited.

Regulatory and safety concerns also pose significant barriers. Unlike synthetic drugs, herbal medicines often lack comprehensive toxicological and pharmacological profiling, which is necessary for approval by global regulatory agencies. The possibility of contamination, adulteration, and herb–drug interactions further raises questions regarding their safety, particularly in patients with complex neurological conditions who may already be on multiple medications. Therefore, rigorous preclinical and clinical trials are essential to establish standardized doses, safety margins, and long-term effects, the future of medicinal plants in neurology lies in an integrative approach combining traditional knowledge with modern scientific validation. Advanced techniques such as metabolomics, network pharmacology, and artificial intelligence can unravel the complex interactions of phytoconstituents and identify multi-target drug candidates [17]. Furthermore, collaboration between traditional healers, pharmacologists, and neuroscientists will be crucial in bridging the gap between ethnomedicine and evidence-based practice. Personalized medicine, guided by genetic and metabolic profiling, may also help tailor plant-based interventions to individual patients, improving treatment outcomes.

In conclusion, while significant progress has been made in validating the role of medicinal plants in managing neurological disorders, challenges related to standardization, bioavailability, and regulatory acceptance remain [18]. Addressing these barriers through interdisciplinary research and technological innovation could unlock the full therapeutic potential of plant-derived compounds, ultimately providing safe, affordable, and effective solutions for neurological health.

6. Challenges and Future Prospects

Despite remarkable progress in validating medicinal plants for neurological disorders, several challenges continue to hinder their effective translation into mainstream therapeutics.

Standardization Issues remain at the forefront. Variability in plant sources, cultivation practices, geographical origin, and extraction techniques often leads to significant differences in phytochemical composition and bioactivity. This lack of uniformity complicates reproducibility across studies and weakens confidence in clinical outcomes. Establishing standardized cultivation protocols, extraction methods, and quality control measures is therefore critical to ensure consistency and reliability of plant-based therapies.

Safety and Toxicity also require urgent attention. While many medicinal plants are used traditionally, their long-term safety and dose optimization in modern therapeutic contexts remain inadequately explored. Certain phytochemicals may exhibit neurotoxic effects at higher concentrations or when administered for extended periods. Rigorous preclinical toxicological assessments, followed by well-designed dose-ranging clinical trials, are essential to confirm safety profiles.

The mechanistic complexity of neurological disorders further complicates plant-based drug development. These disorders often involve multifactorial pathologies, including oxidative stress, neuroinflammation, mitochondrial dysfunction, and neurotransmitter imbalances. Medicinal plants, with their polypharmacological nature, can target multiple pathways simultaneously, but unraveling these mechanisms requires advanced systems biology tools, omics approaches, and network pharmacology, regulatory hurdles persist due to the absence of harmonized international frameworks for the approval of herbal drugs. Regulatory authorities across countries apply differing standards for quality, safety, and efficacy, making global acceptance of plant-based neurological therapies challenging. A unified regulatory framework, backed by WHO or similar organizations, would help streamline approval processes and enhance global access.

Finally, bridging knowledge gaps between traditional healers and modern scientists is paramount. Indigenous knowledge systems offer centuries of empirical wisdom that can guide scientific validation, yet this knowledge is often under-documented or inaccessible. Closer collaboration, participatory research models, and ethical benefit-sharing frameworks are necessary to ensure that traditional wisdom informs scientific innovation while protecting cultural heritage, future research must prioritize integrated clinical trials, novel drug delivery systems (such as nanoformulations), and global standardization initiatives. These efforts will enable the safe, effective, and sustainable utilization of medicinal plants as complementary and alternative strategies for managing neurological disorders.

7. Conclusion

The convergence of traditional knowledge and modern scientific research is opening new pathways for addressing the complex challenges of neurological disorders. For centuries, medicinal plants have played a crucial role in traditional healing systems, offering remedies that are now being revisited with the tools of modern pharmacology, molecular biology, and clinical sciences. This integration is not merely a validation of ancestral wisdom but a transformative step toward developing holistic and sustainable therapeutic options. Medicinal plants are inherently suited for neurological applications due to their polypharmacological nature, enabling them to modulate

multiple pathways such as oxidative stress, neuroinflammation, mitochondrial dysfunction, and neurotransmitter imbalance. Unlike synthetic drugs, which often act on a single target, plant-derived compounds hold the promise of multitargeted neuroprotection. Advances in analytical chemistry, systems biology, and nanotechnology are further enhancing the identification, characterization, and delivery of bioactive phytoconstituents, thereby maximizing their therapeutic efficacy.

References

1. Taylor, J. L. S., Rabe, T., McGaw, L. J., Jäger, A. K., & Van Staden, J. (2001). Towards the scientific validation of traditional medicinal plants. *Plant growth regulation*, *34*(1), 23-37.

2. Mukherjee Pulok, K., Shiv, B., Harwansh Ranjit, K., & Chaudhary Sushil, K. (2014). Shifting paradigm for validation of medicinal plants in Indian traditional medicine. *Indian Drugs*, *51*, 5-14.

3. Perry, E. K., Pickering, A. T., Wang, W. W., Houghton, P., & Perry, N. S. (1998). Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. *The Journal of Alternative and Complementary Medicine*, *4*(4), 419-428.

4. Kumar, V. (2006). Potential medicinal plants for CNS disorders: an overview. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*, *20*(12), 1023-1035.

5. Gurib-Fakim, A. (2006). Medicinal plants: traditions of yesterday and drugs of tomorrow. *Molecular aspects of Medicine*,

6. Karunamoorthi, K., Jegajeevanram, K., Vijayalakshmi, J., & Mengistie, E. (2013). Traditional medicinal plants: a source of phytotherapeutic modality in resource-constrained health care settings. *Journal of Evidence-Based Complementary & Alternative Medicine*, *18*(1), 67-74.

7. Kunwar, R. M., Shrestha, K. P., & Bussmann, R. W. (2010). Traditional herbal medicine in Far-west Nepal: a pharmacological appraisal. *Journal of ethnobiology and ethnomedicine*

8. Sharma, R., Kuca, K., Nepovimova, E., Kabra, A., Rao, M. M., & Prajapati, P. K. (2019). Traditional Ayurvedic and herbal remedies for Alzheimer's disease: from bench to bedside. *Expert review of Neurotherapeutics*, *19*(5), 359-374.

9. Patwardhan, B., & Mashelkar, R. A. (2009). Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward?. *Drug discovery today*, *14*(15-16), 804-811.

10. Togola, A., Austarheim, I., Theïs, A., Diallo, D., & Paulsen, B. S. (2008). Ethnopharmacological uses of Erythrina senegalensis: a comparison of three areas in Mali, and a link between traditional knowledge and modern biological science. *Journal of ethnobiology and ethnomedicine*, *4*(1), 6.

11. Wanzala, W. (2017). Potential of traditional knowledge of plants in the management of arthropods in livestock industry with focus on (Acari) ticks. *Evidence-Based Complementary and Alternative Medicine*, *2017*(1), 8647919.

12. Bencheikh, Noureddine, Amine Elbouzidi, Loubna Kharchoufa, Hayat Ouassou, Ilyass Alami Merrouni, Hamza Mechchate, Imane Es-Safi et al. "Inventory of medicinal plants used traditionally to manage kidney diseases in North-Eastern Morocco: ethnobotanical fieldwork and pharmacological evidence." *Plants* 10, no. 9 (2021): 1966.

13. Sen, S., & Chakraborty, R. (2015). Toward the integration and advancement of herbal medicine: a focus on traditional Indian medicine. *Botanics: Targets and Therapy*, 33-44.

14. Ramawat, K. G., & Goyal, S. (2008). The Indian herbal drugs scenario in global perspectives. *Bioactive molecules and medicinal plants*, 325-347.

15. Njume, C., & Goduka, N. I. (2012). Treatment of diarrhoea in rural African communities: an overview of measures to maximise the medicinal potentials of indigenous plants. *International journal of environmental research and public health*, *9*(11), 3911-3933.

16. Mukherjee, P. K., & Wahile, A. (2006). Integrated approaches towards drug development from Ayurveda and other Indian system of medicines. *Journal of ethnopharmacology*, *103*(1), 25-35.

17. Street, R. A., & Prinsloo, G. (2013). Commercially important medicinal plants of South Africa: a review. *Journal of chemistry*, *2013*(1), 205048.

18. Pan, Si-Yuan, Shu-Feng Zhou, Si-Hua Gao, Zhi-Ling Yu, Shuo-Feng Zhang, Min-Ke Tang, Jian-Ning Sun et al. "New perspectives on how to discover drugs from herbal medicines: CAM′ S outstanding contribution to modern therapeutics." *Evidence-Based Complementary and Alternative Medicine* 2013, no. 1 (2013): 627375.